Profile picture

Professor Stefan H Hohnloser

Johann Wolfgang Goethe University, Frankfurt (Germany)
Membership: FESC Member
Follow
Logo ESC

Contributor content

Atrial fibrillation beyond ablation
Session
Atrial fibrillation beyond ablation
16 April 2023
Anticoagulation management in non-valvular atrial fibrillation: optimising patient outcomes
Session
Anticoagulation management in non-valvular atrial fibrillation: optimising patient outcomes
30 August 2020
Non-vitamin K antagonist oral anticoagulants (NOACs): from new evidence to improved patient outcomes in atrial fibrillation
Session
Non-vitamin K antagonist oral anticoagulants (NOACs): from new evidence to improved patient outcomes in atrial fibrillation
1 September 2019
Catheter ablation and anticoagulation in patients with Atrial Fibrillation (AF): where do we stand?
Session
Catheter ablation and anticoagulation in patients with Atrial Fibrillation (AF): where do we stand?
19 March 2019
Optimizing stroke prevention with NOACs: focus on Atrial Fibrillation (AF) patients with concomitant Acute Coronary Syndrome (ACS)
Session
Optimizing stroke prevention with NOACs: focus on Atrial Fibrillation (AF) patients with concomitant Acute Coronary Syndrome (ACS)
18 March 2019
Stroke prevention in atrial fibrillation: discussing optimal care with NOACs for complex patients
Session
Stroke prevention in atrial fibrillation: discussing optimal care with NOACs for complex patients
28 August 2017
Cancer therapy and arrhythmias
Session
Cancer therapy and arrhythmias
20 June 2017
State-of-the-art: Atrial Fibrillation (AF) ablation in patients on NOACs
Session
State-of-the-art: Atrial Fibrillation (AF) ablation in patients on NOACs
31 August 2015
Exploring the universe of oral anticoagulation in patients with non-valvular atrial fibrillation: continuing the journey
Session
Exploring the universe of oral anticoagulation in patients with non-valvular atrial fibrillation: continuing the journey
30 August 2015
The thrombosis versus bleeding risk dilemma: practical considerations with oral factor Xa inhibition
Session
The thrombosis versus bleeding risk dilemma: practical considerations with oral factor Xa inhibition
1 September 2014

ESC 365 is supported by